MANCHESTER, England, June 7 /CNW/ - Today, (7th June), Cyprotex announces
that it has enhanced the Cloe(R) Screen product offering to include an in
vitro assay that assesses the extent to which a compound binds to liver
microsomes. When used in conjunction with microsomal stability data,
correction for microsomal binding can improve the prediction of a compound's
in vivo clearance and potential for drug-drug interactions. The Cyprotex
Cloe(R) Screen microsomal binding assay was designed in response to requests
from biotechnology and pharmaceutical companies who work with Cyprotex to
evaluate potential drug candidates.
Mr. Robert Morrison Atwater, Cyprotex' Chief Executive Officer, comments
on the launch of the new service "Once again Cyprotex proves itself to be
foremost in the provision of in vitro ADMET services. By offering this service
we are adding to our extensive portfolio of services and reinforcing Cyprotex'
position as a leader within the industry. Similarly to existing Cloe(R) Screen
assays, the microsomal binding assay is invaluable in enabling companies to
make informed decisions when selecting compounds to progress further within
the drug discovery process.'
Cyprotex is a specialist provider of ADME data and pharmacokinetic
predictive services. The unique Cloe(R) Screen technology which couples robust
protocols with state-of-the-art automation enables Cyprotex to offer an
unrivalled combination of high quality, cost effective data with rapid
turnaround. By using data from the Cloe(R) Screen microsomal binding assay in
conjunction with the existing Cloe(R) Screen microsomal stability, a more
accurate prediction of the rate at which a drug is metabolised in vivo is
determined than by means of microsomal stability data alone. The data can also
be applied to improving in vivo drug-drug interaction predictions.
For further information:
For further information: Cyprotex PLC, Dr. Francesca Sadler, Marketing
Manager, Tel: +44-1625-505-100, firstname.lastname@example.org